# Poziotinib in Patients With HER2+ Recurrent Stage IV BC Who Have Received at Least 2 Prior HER2-directed Regimens

> **NCT02418689** · PHASE2 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 106 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** NOV120101 (Poziotinib)

## Key facts

- **NCT ID:** NCT02418689
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2017-06
- **Final completion:** 2021-04
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2022-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02418689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02418689, "Poziotinib in Patients With HER2+ Recurrent Stage IV BC Who Have Received at Least 2 Prior HER2-directed Regimens". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02418689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*